---
title: "VXRT.US (VXRT.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/VXRT.US/news.md"
symbol: "VXRT.US"
name: "VXRT.US"
parent: "https://longbridge.com/en/quote/VXRT.US.md"
datetime: "2026-05-20T11:50:56.395Z"
locales:
  - [en](https://longbridge.com/en/quote/VXRT.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/VXRT.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/VXRT.US/news.md)
---

# VXRT.US (VXRT.US) — Related News

### [Vaxart Urges Shareholder Support Amid Proxy Contest, Updates Pipeline](https://longbridge.com/en/news/286974394.md)
*2026-05-19T22:48:10.000Z*
> Vaxart (VXRT) has urged shareholders to support its board nominees amid a proxy contest, emphasizing the importance of e

### [Vaxart files preliminary proxy, urges support for board as Phase 2b COVID readout, $61M cash runway into Q2 2027](https://longbridge.com/en/news/286969427.md)
*2026-05-19T21:23:00.000Z*
> Vaxart has filed a preliminary proxy and urged shareholders to support its board as it progresses with a Phase 2b COVID-

### [Vaxart submits initial proxy statement and sends letter to investors in recent development.](https://longbridge.com/en/news/286961930.md)
*2026-05-19T20:02:52.000Z*
> Vaxart has submitted an initial proxy statement and communicated with investors regarding recent developments. Additiona

### [09:06 ETJury Returns Full Defense Verdict for Armistice Capital and Its Executives in Vaxart Securities Class Action](https://longbridge.com/en/news/286422512.md)
*2026-05-14T13:07:19.000Z*
> A California federal jury has returned a complete defense verdict for Armistice Capital LLC and its executives, clearing

### [07:00 ETAltesa BioSciences Enrolls First Patient in Phase 2b CARDINAL Clinical Trial Evaluating Vapendavir as Transformational Treatment for Patients with COPD Impacted by Rhinovirus, the Leading Cause of Exacerbations](https://longbridge.com/en/news/285191627.md)
*2026-05-05T11:00:40.000Z*
> Altesa BioSciences has enrolled its first patient in the Phase 2b CARDINAL clinical trial, evaluating vapendavir as a tr

### [Vaxart (VXRT) Expected to Announce Quarterly Earnings on Monday](https://longbridge.com/en/news/285100795.md)
*2026-05-04T17:00:15.000Z*
> Vaxart (OTCMKTS:VXRT) is set to announce its Q1 2026 earnings on May 11, with expectations of $0.02 earnings per share a

### [Vaxart | 10-K: FY2025 Revenue Beats Estimate at USD 237.26 M](https://longbridge.com/en/news/283964597.md)
*2026-04-24T08:54:09.000Z*
### [Vaxart Adds Veteran Biotech Leader to Board](https://longbridge.com/en/news/283900616.md)
*2026-04-23T22:09:40.000Z*
> Vaxart, Inc. has appointed James B. Breitmeyer, M.D., Ph.D., a veteran biotech executive, to its Board of Directors. Thi

### [Vax appoints James B. Breitmeyer to its Board](https://longbridge.com/en/news/283892156.md)
*2026-04-23T20:53:01.000Z*
> Vax has appointed James B. Breitmeyer, M.D., Ph.D. to its Board of Directors, effective immediately. He is the current C